Vertex Pharmaceuticals Reports Q1 Earnings Miss, Raises 2025 Revenue Outlook

Vertex Pharmaceuticals reported first-quarter results that missed analyst expectations, with adjusted earnings per share of $4.06 and revenue of $2.77 billion, both slightly below consensus estimates. Despite continued growth in its cystic fibrosis franchise, U.S. revenues rose while international revenues declined, partly due to intellectual property issues in Russia and competition from illegal copy products. The company raised the low end of its 2025 revenue guidance to $11.85-$12 billion, signaling optimism, although this remains marginally below consensus forecasts. Wall Street sentiment is cautiously optimistic, with an average price target of about $503 per share and a consensus 'Outperform' rating from analysts, though some firms have downgraded the stock due to uncertainties around new products like JOURNAVX. There is also a noted downside risk according to GuruFocus’s fair value estimate, which pegs the stock below current trading levels. Overall, Vertex’s robust portfolio expansion and strategic adjustments are seen as positioning the company for potential long-term gains despite current headwinds.